Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn%s Disease and Irritable Bowel Syndrome Markets Show Strongest Growth

• Publication date: September 2011

Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth Summary GBI Research’s report, “Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth” provides in-depth analysis of the drivers and barriers that affect the global gastrointestinal disorder therapeutics market. The...

Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth

Summary

GBI Research’s report, “Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth” provides in-depth analysis of the drivers and barriers that affect the global gastrointestinal disorder therapeutics market. The report analyzes the markets for gastrointestinal disorder therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2017 for the key geographic regions as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is compiled using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research finds that the gastrointestinal disorder therapeutics market will decline during the period 2010-2017. This decline will primarily be driven by the negative growth of the gastroesophageal reflux disease (GERD) therapeutics market, which is attributed to the loss of drug patents and the entry of generics. However, other key gastrointestinal markets, such as Crohn’s disease and irritable bowel syndrome therapeutics, will continue to grow due to a strong late stage pipeline that will address unmet needs. The global gastrointestinal disorder therapeutics market is a highly fragmented market, where the big players face stiff competition. The forthcoming patent expiries of major drugs have increased competition, driving the consolidation further. This increasing pressure has also driven companies to enter into licensing agreements. This allows companies to expand their product portfolios and improve their competitive positions in the market.

Scope

The scope of this report includes -
- Annualized market data for the gastrointestinal disorder therapeutics market from 2001 to 2010, and forecast to 2017.
- Analysis of the leading therapeutic segments. These include Crohn’s disease, ulcerative colitis, irritable bowel syndrome and gastroesophageal reflux disease.
- Analysis of the gastrointestinal disorder therapeutic markets in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the gastrointestinal disorder therapeutics market, including market size, revenue analysis by top seven geographies, generic share, annual cost of therapy, treatment flow algorithm and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of the pipeline molecules in various phases of drug development.
- Competitive benchmarking of the leading companies. The key companies studied in this report are AstraZeneca, Pfizer Inc, Abbott Laboratories, Johnson & Johnson, Salix Pharmaceuticals, Takeda Pharmaceutical Company Ltd. and Shire Plc.
- Key M&A activities and licensing agreements that have taken place between 2008 and 2011 in the global gastrointestinal disorder therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of the leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Global Pathology Industry

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 8
1.2 List of Figures 11
2 Gastrointestinal Disorder Therapeutics Market: Introduction 13
2.1 Overview 13
2.2 GBI Research Report Guidance 14
3 Global Gastrointestinal Disorder Therapeutics Market: Market Characterization 15
3.1 Market Forecasts 15
3.1.1 Revenue 15
3.1.2 Global Generic Share 16
3.1.3 Annual Cost of Treatment (ACT) 17
3.1.4 Treatment Usage Patterns 18
3.2 Drivers and Restraints for the Global Gastrointestinal Disorder Therapeutics Market 24
3.2.1 Market Drivers 24
3.2.2 Market Restraints 25
4 Gastrointestinal Disorder Therapeutics Market: Geographical Landscape 26
4.1 Revenue Analysis by Geography 26
4.2 The US 28
4.2.1 Revenue 28
4.2.2 Annual Cost of Treatment 29
4.2.3 Treatment Usage Patterns 30
4.3 Top Five Countries of Europe 32
4.3.1 Revenue 32
4.3.2 Revenue by Country 33
4.3.3 Annual Cost of Treatment 35
4.3.4 Treatment Usage Pattern 36
4.4 Japan 38
4.4.1 Revenue 38
4.4.2 Annual Cost of Treatment 39
4.4.3 Treatment Usage Patterns 40
5 Global Gastrointestinal Disorder Therapeutics Market: Therapeutic Landscape 42
5.1 Global Irritable Bowel Syndrome Therapeutics Market Forecasts 42
5.1.1 Introduction 42
5.1.2 Revenue 43
5.1.3 Generic Share 44
5.1.4 Revenue Analysis by Country 45
5.1.5 Annual Cost of Treatment 47
5.1.6 Treatment Flow Algorithm 48
5.1.7 Treatment Usage Patterns 49
5.2 Marketed Products 51
5.2.1 Lotronex 51
5.2.2 Amitiza (Lubiprostone) 51
5.2.3 Bentyl (Dicyclomine hydrochloride) 52
5.3 Drivers and Restraints for the IBS Therapeutics Market 53
5.3.1 Drivers for the IBS Therapeutics Market 53
5.3.2 Restraints for the IBS Therapeutics Market 53
5.4 Global Ulcerative Colitis Therapeutics Market Forecasts 54
5.4.1 Introduction 54
5.4.2 Revenue 55
5.4.3 Generic Share 56
5.4.4 Revenue Analysis by Country 57
5.4.5 Annual Cost of Treatment 59
5.4.6 Treatment Flow Algorithm 60
5.4.7 Treatment Usage Patterns 61
5.5 Major Marketed Products 64
5.5.1 Asacol 64
5.5.2 Lialda 64
5.5.3 Pentasa 64
5.5.4 Apriso 64
5.5.5 Colazal 64
5.5.6 Remicade 65
5.5.7 Azulfidine 65
5.6 Drivers and Restraints for Ulcerative Colitis Therapeutics Market 65
5.6.1 Drivers for the Ulcerative Colitis Therapeutics Market 66
5.6.2 Restraints for the Ulcerative Colitis Therapeutics Market 66
5.7 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Forecasts 67
5.7.1 Introduction 67
5.7.2 Revenue 68
5.7.3 Generic Share 70
5.7.4 Revenue Analysis by Country 71
5.7.5 Annual Cost of Treatment 73
5.7.6 Treatment Flow Algorithm 74
5.7.7 Treatment Usage Patterns 76
5.8 Major Marleted Products 78
5.8.1 Nexium (esomeprazole) 78
5.8.2 Aciphex (rabeprazole sodium) 78
5.8.3 Prevacid (lansoprazole) 78
5.8.4 Prilosec (omeprazole) 78
5.8.5 Protonix (pantoprazole sodium) 79
5.8.6 Tagamet (cimetidine) 79
5.8.7 Pepcid (famotidine) 79
5.8.8 Zantac (ranitidine hydrochloride) 79
5.8.9 Axid (nizatidine) 79
5.9 Drivers and Restraints for the GERD Therapeutics Market 80
5.9.1 Drivers for the GERD Therapeutics Market 80
5.9.2 Restraints for the GERD Therapeutics Market 80
5.10 Global Crohn’s Disease Therapeutics Market Forecasts 81
5.10.1 Introduction 81
5.10.2 Revenue 82
5.10.3 Generic Share 83
5.10.4 Revenue Analysis by Country 84
5.10.5 Annual Cost of Treatment 86
5.10.6 Treatment Flow Algorithm 87
5.10.7 Treatment Usage Patterns 88
5.11 Major Marketed Products 90
5.11.1 Remicade (infliximab) 90
5.11.2 Humira (adalimumab) 90
5.11.3 Tysabri (natalizumab) 91
5.11.4 Entocort EC (budenoside) 91
5.11.5 Cimzia (cetrolizumab pegol) 91
5.12 Drivers and Restraints for the Crohn’s Disease Therapeutics Market 92
5.12.1 Drivers for the Crohn’s Disease Therapeutics Market 92
5.12.2 Restraints for the Crohn’s Disease Therapeutics Market 93
6 Global Gastrointestinal Disorder Therapeutics Market: Pipeline Analysis 94
6.1 Research and Development Pipeline by Phase 94
6.2 Research and Development Pipeline by Indication 95
6.3 Irritable Bowel Syndrome: Research and Development Pipeline 96
6.3.1 Overview 96
6.3.2 Pipeline by Clinical Phases of Development 97
6.4 Promising Drugs under Clinical Development for Irritable Bowel Syndrome 99
6.4.1 Linaclotide (Linaclotide Acetate) 99
6.4.2 Asimadoline 100
6.4.3 Xifaxan (Rifaximin) 101
6.5 Ulcerative Colitis: Research and Development Pipeline 103
6.5.1 Overview 103
6.5.2 Pipeline by Clinical Phases of Development 104
6.6 Promising Drugs under Clinical Development for Ulcerative Colitis 107
6.6.1 Humira (Adalimumab) 107
6.6.2 Golimumab 107
6.6.3 Vedolizumab 108
6.7 Crohn’s Disease: Research and Development Pipeline 109
6.7.1 Overview 109
6.7.2 Pipeline by Clinical Phases of Development 110
6.8 Promising Drugs under Clinical Development for Crohn’s Disease 113
6.8.1 Myoconda 113
6.8.2 Traficet-EN (CCX282) 113
6.8.3 MLN0002 (vedolizumab) 114
6.8.4 Prochymal 115
6.8.5 Stelara 115
6.9 Gastroesophageal reflux disease (GERD): Research and Development Pipeline 116
6.9.1 Overview 116
6.9.2 Pipeline by Clinical Phases of Development 117
6.10 Promising Drugs under Clinical Development for GERD 118
6.10.1 XP19986 118
6.10.2 AZD3355 119
6.10.3 Rozerem 120
6.10.4 Vecam 120
7 Global Gastrointestinal Disorder Therapeutics Market: Competitive Landscape 122
7.1 Overview 122
7.2 Profiles of Major Companies 122
7.2.1 AstraZeneca 122
7.2.2 Abbott Laboratories 124
7.2.3 Johnson & Johnson 125
7.2.4 Salix Pharmaceuticals, Ltd. 126
7.2.5 Takeda Pharmaceutical Company Limited 128
7.2.6 Pfizer, Inc. 129
7.2.7 Shire Plc. 130
8 Global Gastrointestinal Disorder Therapeutics Market: Strategic Consolidations 131
8.1 Mergers and Acquisitions (M&A) 131
8.1.1 Overview 131
8.1.2 Major Mergers and Acquisitions Deals 131
8.1.3 Segmentation by Geography 133
8.1.4 Segmentation by Deal Value 134
8.1.5 Segmentation by Year 135
8.2 Licensing Deals 136
8.2.1 Major Licensing Deals 136
8.2.2 Segmentation by Geography 137
8.2.3 Segmentation by Deal Value 138
8.2.4 Segmentation by Year 139
8.3 Co-development Deals 140
8.3.1 Major Co-development Deals 140
8.3.2 Segmentation by Geography 141
8.3.3 Segmentation by Year 142
9 Global Gastrointestinal Disorder Therapeutics Market : Appendix 143
9.1 Market Definitions 143
9.2 Abbreviations 143
9.3 Research Methodology 144
9.3.1 Coverage 144
9.3.2 Secondary Research 145
9.3.3 Primary Research 145
9.4 Therapeutic Landscape 146
9.4.1 Epidemiology-based Forecasting 146
9.4.2 Market Size by Geography 148
9.5 Geographical Landscape 149
9.6 Pipeline Analysis 149
9.7 Competitive Landscape 149
9.7.1 Expert Panel Validation 149
9.8 Contact Us 149
9.9 Disclaimer 149
9.10 Sources 150

1.1 List of Tables

Table 1: Gastrointestinal Disorder Therapeutics Market, Global, Revenue ($bn), 2002-2010 15
Table 2: Gastrointestinal Disorder Therapeutics Market, Global, Revenue ($bn), 2010-2017 15
Table 3: Gastrointestinal Disorder Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 17
Table 4: Gastrointestinal Disorder Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 17
Table 5: Gastrointestinal Disorder Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2010 18
Table 6: Gastrointestinal Disorder Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2010-2017 19
Table 7: Gastrointestinal Disorder Therapeutics Market, Global Revenue by Country ($m), 2002-2010 27
Table 8: Gastrointestinal Disorder Therapeutics Market, Global Revenue by Country ($m), 2010-2017 27
Table 9: Gastrointestinal Disorder Therapeutics Market, The US, Revenue ($bn), 2002-2010 28
Table 10: Gastrointestinal Disorder Therapeutics Market, The US, Revenue ($bn), 2010-2017 28
Table 11: Gastrointestinal Disorder Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2010 29
Table 12: Gastrointestinal Disorder Therapeutics Market, The US, Annual Cost of Treatment ($), 2010-2017 29
Table 13: Gastrointestinal Disorder Therapeutics Market, The US, Treatment Usage Patterns (Millions), 2002-2010 30
Table 14: Gastrointestinal Disorder Therapeutics Market, The US, Treatment Usage Patterns (Millions), 2010-2017 31
Table 15: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002-2010 32
Table 16: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2010-2017 32
Table 17: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($m), 2002-2010 33
Table 18: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($m), 2002-2010 34
Table 19: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 35
Table 20: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 35
Table 21: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2002-2010 36
Table 22: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2010-2017 37
Table 23: Gastrointestinal Disorder Therapeutics Market, Japan, Revenue ($bn), 2002-2010 38
Table 24: Gastrointestinal Disorder Therapeutics Market, Japan, Revenue ($bn), 2010-2017 38
Table 25: Gastrointestinal Disorder Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010 39
Table 26: Gastrointestinal Disorder Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2017 39
Table 27: Gastrointestinal Disorder Therapeutics Market, Japan, Treatment Usage Patterns (Millions), 2002-2010 40
Table 28: Gastrointestinal Disorder Therapeutics Market, Japan, Treatment Usage Patterns (Millions), 2010-2017 41
Table 29: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2002-2010 43
Table 30: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2010-2017 43
Table 31: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue by Country ($m), 2002-2010 45
Table 32: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue by Country ($m), 2010-2017 46
Table 33: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 47
Table 34: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 47
Table 35: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2010 49
Table 36: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2010-2017 50
Table 37: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2002-2010 55
Table 38: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2010-2017 55
Table 39: Ulcerative Colitis Therapeutics Market, Global, Revenue by Country ($m), 2002-2010 57
Table 40: Ulcerative Colitis Therapeutics Market, Global, Revenue by Country ($m), 2010-2017 58
Table 41: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 59
Table 42: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 59
Table 43: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2002-2010 62
Table 44: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2010-2017 62
Table 45: GERD Therapeutics Market, Global, Revenue ($bn), 2002-2010 68
Table 46: GERD Therapeutics Market, Global, Revenue ($bn), 2010-2017 68
Table 47: GERD Therapeutics Market, Global, Revenue by Country ($m), 2002-2010 71
Table 48: GERD Therapeutics Market, Global, Revenue by Country ($m), 2010-2017 72
Table 49: GERD Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 73
Table 50: GERD Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 73
Table 51: GERD Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2010 76
Table 52: GERD Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2010-2017 77
Table 53: Crohn’s Disease Therapeutics Market, Global, Revenue ($m), 2002-2010 82
Table 54: Crohn’s Disease Therapeutics Market, Global, Revenue ($m), 2010-2017 82
Table 55: Crohn’s Disease Therapeutics Market, Global, Revenue by Country ($m), 2002-2010 84
Table 56: Crohn’s Disease Therapeutics Market, Global, Revenue by Country ($m), 2010-2017 85
Table 57: Crohn’s Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 86
Table 58: Crohn’s Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 86
Table 59: Crohn’s Disease Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2002-2010 88
Table 60: Crohn’s Disease Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2002-2010 89
Table 61: Gastrointestinal Disorder Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 94
Table 62: Gastrointestinal Disorder Therapeutics Market, Global, Number of Molecules in Pipeline, 2011 95
Table 63: Irritable Bowel Syndrome Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 96
Table 64: Irritable Bowel Syndrome Therapeutics Market, Global, Discovery Pipeline Molecules, 2011 97
Table 65: Irritable Bowel Syndrome Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011 97
Table 66: Irritable Bowel Syndrome Therapeutics Market, Global, Phase I Pipeline Molecules, 2011 97
Table 67: Irritable Bowel Syndrome Therapeutics Market, Global, Phase II Pipeline Molecules, 2011 98
Table 68: Irritable Bowel Syndrome Therapeutics Market, Global, Phase III/NDA filed Pipeline Molecules, 2011 98
Table 69: Ulcerative Colitis Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 103
Table 70: Ulcerative Colitis Therapeutics Market, Discovery Pipeline Molecules, 2011 104
Table 71: Ulcerative Colitis Therapeutics Market, Preclinical Pipeline Molecules, 2011 104
Table 72: Ulcerative Colitis Therapeutics Market, Phase I Molecules, 2011 104
Table 73: Ulcerative Colitis Therapeutics Market, Phase II Molecules, 2011 105
Table 74: Ulcerative Colitis Therapeutics Market, Phase III/NDA Filed Molecules, 2011 106
Table 75: Crohn’s Disease Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 109
Table 76: Crohn’s Disease Therapeutics Market, Discovery Pipeline Molecules, 2011 110
Table 77: Crohn’s Disease Therapeutics Market, Preclinical Pipeline Molecules, 2011 110
Table 78: Crohn’s Disease Therapeutics Market, Phase I Pipeline Molecules, 2011 110
Table 79: Crohn’s Disease Therapeutics Market, Phase II Pipeline Molecules, 2011 111
Table 80: Crohn’s Disease Therapeutics Market, Phase III Pipeline Molecules, 2011 112
Table 81: GERD Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 116
Table 82: GERD Therapeutics Market, Preclinical Pipeline Molecules, 2011 117
Table 83: GERD Therapeutics Market, Phase I Pipeline Molecules, 2011 117
Table 84: GERD Therapeutics Market, Phase II Pipeline Molecules, 2011 117
Table 85: GERD Therapeutics Market, Phase III Pipeline Molecules, 2011 118
Table 86: Gastrointestinal Disorder Therapeutics Market, Pfizer – Gastrointestinal R&D Pipeline, 2011 129
Table 87: Gastrointestinal Disorder Therapeutics Market, Shire Plc. – Gastrointestinal Pipeline Products, 2011 130
Table 88: Gastrointestinal Disorder Therapeutics Market, Global, Major M&A Deals, 2008-2011 131
Table 89: Gastrointestinal Disorder Therapeutics Market, Global, M&A Deals by Geography, 2004-2011 133
Table 90: Gastrointestinal Disorder Therapeutics Market, Global, M&A Deals by Value, 2004-2011 134
Table 91: Gastrointestinal Disorder Therapeutics Market, Global, M&A Deals by Year, 2004-2011 135
Table 92: Gastrointestinal Disorder Therapeutics Market, Global, Major Licensing Deals, 2008-2011 136
Table 93: Gastrointestinal Disorder Therapeutics Market, Global, Licensing Deals by Geography, 2004-2011 137
Table 94: Gastrointestinal Disorder Therapeutics Market, Global, Licensing Deals by Year, 2004-2011 139
Table 95: Gastrointestinal Disorder Therapeutics Market, Global, Major Co-Development Deals, 2008-2011 140
Table 96: Gastrointestinal Disorder Therapeutics Market, Global, Co-Development Deals by Geography, 2004-2011 141
Table 97: Gastrointestinal Disorder Therapeutics Market, Global, Co-Development Deals by Year, 2004-2011 142

1.2 List of Figures

Figure 1: Gastrointestinal Disorder Therapeutics Market, Global, Revenue ($bn), 2002-2017 15
Figure 2: Gastrointestinal Disorder Therapeutics Market, Global, Generic Share (%), 2010-2017 16
Figure 3: Gastrointestinal Disorder Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 17
Figure 4: Gastrointestinal Disorder Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2017 18
Figure 5: Gastrointestinal Disorder Therapeutics Market, Global, Diseased Population (Millions), 2002-2017 20
Figure 6: Gastrointestinal Disorder Therapeutics Market, Global, Treatment Seeking Population (Millions), 2002-2017 21
Figure 7: Gastrointestinal Disorder Therapeutics Market, Global, Diagnosed Population (Millions), 2002-2017 22
Figure 8: Gastrointestinal Disorder Therapeutics Market, Global, Treated Population (Millions), 2002-2017 23
Figure 9: Gastrointestinal Disorder Therapeutics Market, Global, Market Drivers and Restraints, 2011 24
Figure 10: Gastrointestinal Disorder Therapeutics Market, Global, Revenue by Country ($m), 2002-2017 26
Figure 11: Gastrointestinal Disorder Therapeutics Market, The US, Revenue ($bn), 2002-2017 28
Figure 12: Gastrointestinal Disorder Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2017 29
Figure 13: Gastrointestinal Disorder Therapeutics Market, The US, Treatment Usage Patterns (Millions), 2002-2017 30
Figure 14: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002-2017 32
Figure 15: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($m), 2002-2017 33
Figure 16: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 35
Figure 17: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2002-2017 36
Figure 18: Gastrointestinal Disorder Therapeutics Market, Japan, Revenue ($bn), 2002-2017 38
Figure 19: Gastrointestinal Disorder Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2017 39
Figure 20: Gastrointestinal Disorder Therapeutics Market, Japan, Treatment Usage Patterns (Millions), 2002-2017 40
Figure 21: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2002-2017 43
Figure 22: Irritable Bowel Syndrome Therapeutics Market, Global, Generic Share (%), Global, 2010, 2017 44
Figure 23: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue by Country ($m), 2002-2017 45
Figure 24: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 47
Figure 25: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Flow Algorithm for IBS, 2011 48
Figure 26: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2017 49
Figure 27: Irritable Bowel Syndrome Therapeutics Market, Global, Market Drivers and Restraints, 2011 53
Figure 28: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2002-2017 55
Figure 29: Ulcerative Colitis Therapeutics Market, Generic Share (%), Global, 2010-2017 56
Figure 30: Ulcerative Colitis Therapeutics Market, Global, Revenue by Country ($m), 2002-2017 57
Figure 31: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 59
Figure 32: Ulcerative Colitis Therapeutics Market, Global, Treatment Flow Algorithm for Ulcerative Colitis, 2011 60
Figure 33: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2002-2017 61
Figure 34: Ulcerative Colitis Therapeutics Market, Global, Market Drivers and Restraints, 2011 65
Figure 35: GERD Therapeutics Market, Global, Revenue ($bn), 2002-2017 68
Figure 36: GERD Therapeutics Market, Generic Share (%), Global, 2010, 2017 70
Figure 37: GERD Therapeutics Market, Global, Revenue by Country ($m), 2002-2017 71
Figure 38: GERD Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 73
Figure 39: GERD Therapeutics Market, Global, Treatment Flow Algorithm for Self and Primary Care Treatment of GERD, 2011 74
Figure 40: GERD Therapeutics Market, Global, Treatment Flow Algorithm for Secondary Care Treatment of GERD, 2011 75
Figure 41: GERD Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2017 76
Figure 42: GERD Therapeutics Market, Market Drivers and Restraints, 2011 80
Figure 43: Crohn’s Disease Therapeutics Market, Global, Revenue ($m), 2002-2017 82
Figure 44: Crohn’s Disease Therapeutics Market, Generic Share (%), Global, 2010, 2017 83
Figure 45: Crohn’s Disease Therapeutics Market, Global, Revenue by Country ($m), 2002-2017 84
Figure 46: Crohn’s Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 86
Figure 47: Crohn’s Disease Therapeutics Market, Global, Treatment Algorithm for Crohn’s Disease, 2011 87
Figure 48: Crohn’s Disease Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2002-2017 88
Figure 49: Crohn’s Disease Therapeutics Market, Global, Market Drivers and Restraints, 2011 92
Figure 50: Gastrointestinal Disorder Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 94
Figure 51: Gastrointestinal Disorder Therapeutics Market, Global, Pipeline Analysis, (%), 2011 95
Figure 52: Irritable Bowel Syndrome Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 96
Figure 53: Ulcerative Colitis Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 103
Figure 54: Crohn’s Disease Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 109
Figure 55: GERD Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 116
Figure 56: Gastrointestinal Disorder Therapeutics Market, AstraZeneca, SWOT Analysis, 2011 123
Figure 57: Gastrointestinal Disorder Therapeutics Market, Abbott Laboratories, SWOT Analysis 2011 124
Figure 58: Gastrointestinal Disorder Therapeutics Market, Johnson & Johnson, SWOT Analysis, 2011 125
Figure 59: Gastrointestinal Disorder Therapeutics Market, Salix Pharmaceuticals, Ltd., SWOT Analysis, 2011 127
Figure 60: Gastrointestinal Disorder Therapeutics Market, Takeda Pharmaceutical Company Limited, SWOT Analysis, 2011 128
Figure 61: Gastrointestinal Disorder Therapeutics Market, Pfizer, Inc., SWOT Analysis, 2011 129
Figure 62: Gastrointestinal Disorder Therapeutics Market, Shire Plc, SWOT Analysis, 2011 130
Figure 63: Gastrointestinal Disorder Therapeutics Market, Global, M&A Deals by Geography, 2004-2011 133
Figure 64: Gastrointestinal Disorder Therapeutics Market, Global, M&A Deals by Value ($m), 2004-2011 134
Figure 65: Gastrointestinal Disorder Therapeutics Market, Global, M&A Deals by Year, 2004-2011 135
Figure 66: Gastrointestinal Disorder Therapeutics Market, Global, Licensing Deals by Geography, 2004-2011 137
Figure 67: Gastrointestinal Disorder Therapeutics Market, Global, Licensing Deals by Value ($m), 2004-2011 138
Figure 68: Gastrointestinal Disorder Therapeutics Market, Global, Licensing Deals by Year, 2004-2011 139
Figure 69: Gastrointestinal Disorder Therapeutics Market, Global, Co-Development Deals by Geography, 2004-2011 141
Figure 70: Gastrointestinal Disorder Therapeutics Market, Global, Co-Development Deals by Year, 2004-2011 142
Figure 71: GBI Research Market Forecasting Model 148

Companies Mentioned
AstraZeneca
Abbott Laboratories
Johnson & Johnson
Salix Pharmaceuticals, Ltd.
Takeda Pharmaceutical Company Limited
Pfizer, Inc.
Shire Plc.